Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Ninlaro (ixazomib)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Takeda

Drug class:

Proteasome inhibitor

Related drugs:

‹

bortezomib (90)

carfilzomib (18)

bortezomib (90)

carfilzomib (18)

›

No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	lenalidomide + ixazomib Sensitive: A1 - Approval lenalidomide + ixazomib Sensitive : A1	lenalidomide + ixazomib Sensitive: A1 - Approval lenalidomide + ixazomib Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	ixazomib Sensitive: A2 - Guideline ixazomib Sensitive : A2	ixazomib Sensitive: A2 - Guideline ixazomib Sensitive : A2
No biomarker	Waldenstrom Macroglobulinemia	No biomarker	Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: A2 - Guideline rituximab + ixazomib Sensitive : A2	rituximab + ixazomib Sensitive: A2 - Guideline rituximab + ixazomib Sensitive : A2
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	ixazomib + pomalidomide Sensitive: A2 - Guideline ixazomib + pomalidomide Sensitive : A2	ixazomib + pomalidomide Sensitive: A2 - Guideline ixazomib + pomalidomide Sensitive : A2
CXCR4 mutation	Waldenstrom Macroglobulinemia	CXCR4 mutation	Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: C2 – Inclusion Criteria rituximab + ixazomib Sensitive : C2	rituximab + ixazomib Sensitive: C2 – Inclusion Criteria rituximab + ixazomib Sensitive : C2
MYD88 L265P	Waldenstrom Macroglobulinemia	MYD88 L265P	Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: C2 – Inclusion Criteria rituximab + ixazomib Sensitive : C2	rituximab + ixazomib Sensitive: C2 – Inclusion Criteria rituximab + ixazomib Sensitive : C2
Chr t(14;16)	Multiple Myeloma	Chr t(14;16)	Multiple Myeloma	ixazomib Sensitive: C2 – Inclusion Criteria ixazomib Sensitive : C2	ixazomib Sensitive: C2 – Inclusion Criteria ixazomib Sensitive : C2
CXCR4 G336X	Waldenstrom Macroglobulinemia	CXCR4 G336X	Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: C3 – Early Trials rituximab + ixazomib Sensitive : C3	rituximab + ixazomib Sensitive: C3 – Early Trials rituximab + ixazomib Sensitive : C3
CXCR4 S338X	Waldenstrom Macroglobulinemia	CXCR4 S338X	Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: C3 – Early Trials rituximab + ixazomib Sensitive : C3	rituximab + ixazomib Sensitive: C3 – Early Trials rituximab + ixazomib Sensitive : C3
CXCR4 H350fs*	Waldenstrom Macroglobulinemia	CXCR4 H350fs*	Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: C3 – Early Trials rituximab + ixazomib Sensitive : C3	rituximab + ixazomib Sensitive: C3 – Early Trials rituximab + ixazomib Sensitive : C3
CXCR4 S338X + TP53 R196X	Waldenstrom Macroglobulinemia	CXCR4 S338X + TP53 R196X	Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: C3 – Early Trials rituximab + ixazomib Sensitive : C3	rituximab + ixazomib Sensitive: C3 – Early Trials rituximab + ixazomib Sensitive : C3
CXCR4 K327fs*	Waldenstrom Macroglobulinemia	CXCR4 K327fs*	Waldenstrom Macroglobulinemia	rituximab + ixazomib Sensitive: C3 – Early Trials rituximab + ixazomib Sensitive : C3	rituximab + ixazomib Sensitive: C3 – Early Trials rituximab + ixazomib Sensitive : C3